Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rituximab biosimilar by Shanghai Henlius Biotech for Follicular Lymphoma: Likelihood of Approval
Rituximab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Follicular Lymphoma. According to...
Rituximab biosimilar by Shanghai Henlius Biotech for Follicular Lymphoma: Likelihood of Approval
Rituximab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Follicular Lymphoma. According to...
Rituximab biosimilar by Shanghai Henlius Biotech for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Rituximab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Extranodal Marginal Zone B-Cell...
Rituximab biosimilar by Celltrion for Primary CNS Lymphoma: Likelihood of Approval
Rituximab biosimilar is under clinical development by Celltrion and currently in Phase II for Primary CNS Lymphoma. According to GlobalData,...
Rituximab biosimilar by Shanghai Henlius Biotech for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Rituximab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Splenic Marginal Zone B-Cell...
Rituximab biosimilar by Shanghai Henlius Biotech for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Rituximab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Splenic Marginal Zone B-Cell...
Rituximab biosimilar by Apotex for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Rituximab biosimilar is under clinical development by Apotex and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to...
Rituximab biosimilar by Apotex for Non-Hodgkin Lymphoma: Likelihood of Approval
Rituximab biosimilar is under clinical development by Apotex and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...
Rituximab biosimilar by Nichi-Iko Pharmaceutical for Lymphoma: Likelihood of Approval
Rituximab biosimilar is under clinical development by Nichi-Iko Pharmaceutical and currently in Phase I for Lymphoma. According to GlobalData, Phase...